Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the sale, the insider directly owned 611,135 shares in the company, valued at $2,695,105.35. This represents a 16.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.12 during mid-day trading on Monday, hitting $4.13. The company’s stock had a trading volume of 24,371,056 shares, compared to its average volume of 29,091,332. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The firm has a market capitalization of $2.15 billion, a P/E ratio of -2.29 and a beta of 0.94. The firm has a 50-day simple moving average of $4.78 and a 200 day simple moving average of $5.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The firm had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was down 80.1% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Finally, UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after buying an additional 4,149,346 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 10.3% during the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after acquiring an additional 3,708,975 shares during the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals during the 2nd quarter worth about $16,040,000. Bank Pictet & Cie Europe AG acquired a new position in Recursion Pharmaceuticals in the 3rd quarter valued at about $7,954,000. Finally, Geode Capital Management LLC raised its stake in Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.